AU3889595A - Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein - Google Patents
Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use thereinInfo
- Publication number
- AU3889595A AU3889595A AU38895/95A AU3889595A AU3889595A AU 3889595 A AU3889595 A AU 3889595A AU 38895/95 A AU38895/95 A AU 38895/95A AU 3889595 A AU3889595 A AU 3889595A AU 3889595 A AU3889595 A AU 3889595A
- Authority
- AU
- Australia
- Prior art keywords
- oligonucleotides
- cell proliferation
- smooth muscle
- muscle cell
- inhibiting smooth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
- 230000004663 cell proliferation Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31845894A | 1994-10-05 | 1994-10-05 | |
| US318458 | 1994-10-05 | ||
| PCT/US1995/012770 WO1996011266A2 (fr) | 1994-10-05 | 1995-10-03 | Procede d'inhibition de la proliferation des cellules musculaires lisses et oligonucleotides utilises dans celui-ci |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU3889595A true AU3889595A (en) | 1996-05-02 |
Family
ID=23238272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU38895/95A Abandoned AU3889595A (en) | 1994-10-05 | 1995-10-03 | Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU3889595A (fr) |
| WO (1) | WO1996011266A2 (fr) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7008765B1 (en) | 1997-04-10 | 2006-03-07 | The Johns Hopkins University | PCA3, PCA3 genes, and methods of use |
| CA2385477C (fr) | 1999-09-29 | 2009-11-03 | Diagnocure Inc. | Variantes l'arnm du pca3 dans les tissus benins et malins de la prostate |
| US20050282170A1 (en) | 2003-02-07 | 2005-12-22 | Diagnocure Inc. | Method to detect prostate cancer in a sample |
| CA2491067A1 (fr) | 2004-12-24 | 2006-06-24 | Stichting Katholieke Universiteit | Rapport entre arnm dans les sediments urinaires ou l'urine en tant que marqueur pronostique du cancer de la prostate |
| JP5635412B2 (ja) | 2007-12-04 | 2014-12-03 | アルニラム ファーマスーティカルズ インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 標的化脂質 |
| EP3100718B1 (fr) | 2008-01-02 | 2019-11-27 | Arbutus Biopharma Corporation | Compositions améliorées et procédés d'administration d'acides nucléiques |
| AU2009238175C1 (en) | 2008-04-15 | 2023-11-30 | Arbutus Biopharma Corporation | Novel lipid formulations for nucleic acid delivery |
| EP2350043B9 (fr) | 2008-10-09 | 2014-08-20 | TEKMIRA Pharmaceuticals Corporation | Lipides aminés améliorés et procédés d'administration d'acides nucléiques |
| CN111909020A (zh) | 2008-11-10 | 2020-11-10 | 阿布特斯生物制药公司 | 用于递送治疗剂的脂质和组合物 |
| CA2764609C (fr) | 2009-06-10 | 2018-10-02 | Alnylam Pharmaceuticals, Inc. | Lipide cationique ameliore de formule i |
| EP2449114B9 (fr) | 2009-07-01 | 2017-04-19 | Protiva Biotherapeutics Inc. | Formulations lipidiques inédites permettant l'administration d'agents thérapeutiques en direction de tumeurs solides |
| AU2010328336B2 (en) | 2009-12-07 | 2017-03-02 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
| WO2011075656A1 (fr) | 2009-12-18 | 2011-06-23 | The University Of British Columbia | Procédés et compositions pour l'administration d'acides nucléiques |
| WO2012016184A2 (fr) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Procédés et compositions pour la délivrance d'agents actifs |
| WO2012016188A2 (fr) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Procédés et compositions pour l'administration d'agents actifs |
| EP3202760B1 (fr) | 2011-01-11 | 2019-08-21 | Alnylam Pharmaceuticals, Inc. | Lipides pégylés et leur utilisation pour l'administration de médicaments |
| JP6250543B2 (ja) | 2011-09-27 | 2017-12-20 | アルニラム・ファーマシューティカルズ・インコーポレーテッド | ジ脂肪族置換ｐｅｇ化脂質 |
| RS58077B1 (sr) | 2012-02-24 | 2019-02-28 | Arbutus Biopharma Corp | Trialkil katjonski lipidi i postupci njihove primene |
| CA3177846A1 (fr) | 2013-07-11 | 2015-01-15 | Alnylam Pharmaceuticals, Inc. | Conjugues ligands d'oligonucleotides et procede pour leur preparation |
| EP4121018A4 (fr) | 2020-03-17 | 2024-07-03 | Genevant Sciences Gmbh | Lipides cationiques pour l'administration de nanoparticules lipidiques d'agents thérapeutiques à des cellules stellaires hépatiques |
| CA3201998A1 (fr) | 2020-12-18 | 2022-06-23 | James Heyes | Lipides peg et nanoparticules lipidiques |
| IL307298A (en) | 2021-03-31 | 2023-11-01 | Entrada Therapeutics Inc | Cell-penetrating circular peptides |
| KR20240012425A (ko) | 2021-05-10 | 2024-01-29 | 엔트라다 테라퓨틱스, 인크. | 세포내 치료제를 위한 조성물 및 방법 |
| WO2022240721A1 (fr) | 2021-05-10 | 2022-11-17 | Entrada Therapeutics, Inc. | Compositions et méthodes de modulation de l'activité du facteur 5 de régulation de l'interféron (irf-5) |
| KR20240038967A (ko) | 2021-06-23 | 2024-03-26 | 엔트라다 테라퓨틱스, 인크. | Cug 반복을 표적화하기 위한 안티센스 화합물 및 방법 |
| CA3227661A1 (fr) | 2021-08-05 | 2023-02-09 | Weimin Wang | Derives de ribose modifies par 1'-alkyle et procedes d'utilisation |
| US20230241224A1 (en) | 2021-09-22 | 2023-08-03 | Sanegene Bio Usa Inc. | 2'-alkyl or 3'- alkyl modified ribose derivatives and methods of use |
| WO2023059695A1 (fr) | 2021-10-05 | 2023-04-13 | Sanegene Bio Usa Inc. | Dérivés de cyclopentane polyhydroxylés et procédés d'utilisation |
| CN118922401A (zh) | 2022-01-31 | 2024-11-08 | 盖纳万科学有限公司 | 用于脂质纳米颗粒的可电离阳离子脂质 |
| US20250114476A1 (en) | 2022-01-31 | 2025-04-10 | Genevant Sciences Gmbh | Poly(alkyloxazoline)-lipid conjugates and lipid particles containing same |
| CA3252536A1 (fr) | 2022-02-22 | 2023-08-31 | Sanegene Bio Usa Inc. | Dérivés de ribonucléotides carbocycliques modifiés en position 5' et procédés d'utilisation |
| AU2023307152A1 (en) | 2022-07-11 | 2025-01-09 | Sanegene Bio Usa Inc. | Optimized 2'- modified ribose derivatives and methods of use |
| US20250018045A1 (en) | 2023-05-03 | 2025-01-16 | Sanegene Bio Usa Inc. | Lipid-based conjugates for systemic, central nervous system, peripheral nervous system, and ocular delivery |
| WO2025024523A1 (fr) | 2023-07-24 | 2025-01-30 | Sanegene Bio Usa Inc. | Agent d'amélioration à base de lipides pour l'administration d'arn et une thérapie à arn |
| WO2025052278A1 (fr) | 2023-09-05 | 2025-03-13 | Genevant Sciences Gmbh | Lipides cationiques à base de pyrrolidine pour administration de nanoparticules lipidiques d'agents thérapeutiques à des cellules stellaires hépatiques |
| WO2025133951A1 (fr) | 2023-12-21 | 2025-06-26 | Genevant Sciences Gmbh | Lipides ionisables appropriés pour des nanoparticules lipidiques |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07501204A (ja) * | 1991-06-28 | 1995-02-09 | マサチューセッツ インスティテュート オブ テクノロジー | 局所的オリゴヌクレオチド療法 |
| US5523389A (en) * | 1992-09-29 | 1996-06-04 | Isis Pharmaceuticals, Inc. | Inhibitors of human immunodeficiency virus |
-
1995
- 1995-10-03 AU AU38895/95A patent/AU3889595A/en not_active Abandoned
- 1995-10-03 WO PCT/US1995/012770 patent/WO1996011266A2/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO1996011266A2 (fr) | 1996-04-18 |
| WO1996011266A3 (fr) | 1996-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU3889595A (en) | Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein | |
| HUP9802445A3 (en) | Liposomal oligonucleotide compositions and process for inhibiting the human raf | |
| IL117177A0 (en) | Benzopyran-containing compounds and method for their use | |
| AU9202698A (en) | Exchange method and apparatus | |
| HUP9801569A3 (en) | Process for polymerizing and reactor | |
| HU9502587D0 (en) | Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation | |
| HU9601465D0 (en) | Metallocenes, method for their preparation and use | |
| SG68652A1 (en) | Coating apparatus and coating method | |
| SG90130A1 (en) | Coating apparatus and coating method | |
| AU5688898A (en) | Catheter exchange method and apparatus | |
| AU2000246432A1 (en) | Sphincter treatment apparatus | |
| AU7125198A (en) | Defibrillator method and apparatus | |
| EP0761317A4 (fr) | Procede de depot d'une revetement et appareil associe | |
| AU4139196A (en) | Method and composition for antiviral therapy | |
| AU5439996A (en) | Compositions and methods for treating pain | |
| AU6945298A (en) | Improved wastewater treatment apparatus and method | |
| AUPO673997A0 (en) | Muscle function assessment apparatus and method | |
| GB2298713B (en) | Method and composition | |
| IL118483A0 (en) | Methods for inhibiting vascular smooth muscle cell migration | |
| AU2667599A (en) | Rack exercise system and method | |
| EP1100981A4 (fr) | Procedes et appareil de protection cathodique | |
| EP0917768A3 (fr) | Procede et appareil relatifs a un correlateur | |
| ZA95701B (en) | Rivets-nails and methods for their implementation | |
| GB9512529D0 (en) | Cell treatment | |
| GB9518154D0 (en) | Oligonucleotides and their use |